• Explore /
  • Poster
  • / ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.

ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.

Abstract Poster

Authors

null

Do-Youn Oh

Seoul National University Hospital, Seoul, South Korea

Do-Youn Oh , Hyun Cheol Chung , Young Hyuck Im , Chia Jui Yen , Yee Chao , ZheZhen Li , Xin Wang , Jin Wang , Huiyan Li , Yoon-Koo Kang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Antibodies

Clinical Trial Registration Number

Registered, NCT number pending will provide as soon as available

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS3145)

DOI

10.1200/JCO.2020.38.15_suppl.TPS3145

Abstract #

TPS3145

Poster Bd #

209

Abstract Disclosures

Similar Posters

First Author: Keun Wook Lee

First Author: Keun Wook Lee

First Author: Lin Shen

First Author: Xiaojia Wang